


FORM PTO-1449 (Modified)	Attorney Docket No. 018623-005091/EPI 0050.91US	Serial No.: 09/017,524
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: Ralph T. Kubo et al.	
	Filing Date: 2/3/98	Group: not assigned



Reference Designation **U.S. PATENT DOCUMENTS**

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
<u>WJ</u> A1	5,342,774	08/30/94	Boon et al.	435	240.2	12/12/91
<u>MD</u> A2	5,200,320	04/06/93	Sette et al.	435	7.24	12/07/87
<u>MD</u> A3	5,405,940	04/11/95	Boon et al.	530	328	08/31/92

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)
<u>MD</u> B1	WO 94/05304 (PCT/US93/08157)	03/17/94	PCT	C07K	7/06	
<u>MD</u> B2	WO 92/21033	<u>11/26/1992</u>	PCT			yes <u>MD</u>
<u>MD</u> B3	WO 94/11738	<u>5/26/1994</u>	PCT			<u>MD</u>
<u>MD</u> B4	WO 92/02543	2/92	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<u>MD</u> C1	Celis, E. et al., Proc. Nat'l. Acad. Sci. USA 91: 2105-2109 (March, 1994), Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes".
C2	Ding, M. et al., Biochem. Biophys. Res. Commun. 202(1): 549-555 (July 15, 1994), "Cloning and analysis of MAGE-1-related genes".
C3	Gaugler, B. et al., J. Exp. Med. 179(3): 921-930 (March 1, 1994), "Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes".
C4	Oakes, M.K. et al., Cancer Res. 54: 1627-1629 (April 1, 1994), "Molecular cytogenetic mapping of the human melanoma antigen (MAGE) gene family to chromosome region Xq27-qtr: implications for MAGE immunotherapy".
C5	Paul, W.F. (ed.), Fundamental Immunology, 3 rd ed., pp- 976-978 (1993), Raven Press, NY
C6	Traversari, C. et al., J. Exp. Med. 176: 1453-1457 (November, 1992), "A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E".
<u>MD</u> C7	Robbins Pathologic Basis of Disease, 4 th edition (R.S. Cotran et: al., ed.), pp. 296-299 (1989), W.B. Saunders Co., Philadelphia

Handwritten signature 12/30/00

FORM PTO-1449 (Modified)		Attorney Docket No. 018623-005091/EPI 0050.91US	Serial No.: 09/017,524
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Ralph T. Kubo et al.	
		Filing Date: 2/3/98	Group: not assigned
<u>W</u> C8	Weynants, P. et al., <i>J. Cancer</i> , 56: 826-829 (1994), "Expression of MAGE genes by non-small-cell lung carcinomas".		
C9	Zakut, R. et al., <i>Cancer Res.</i> 53: 5-8 (January 1, 1993), "Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines".		
C10	Urban, J.L., et al., "Autoimmune T Cells: Immune Recognition of Normal and Variant Peptide Epitopes and Peptide-Based Therapy," <i>Cell</i> 59:257-271 (October 20, 1989).		
C11	Wraith, D.C., et al., "Antigen Recognition in Autoimmune Encephalomyelitis and the Potential for Peptide-Mediated Immunotherapy," <i>Cell</i> 59:247-255 (October 20, 1989).		
C12	Parker, K.C., et al., "Peptide Binding to HLA-A2 and HLA-B27 Isolated from <i>Escherichia coli</i> ," <i>J. Biol. Chem.</i> 267(8):5451-5459 (March 15, 1992).		
C13	Morrison, J., et al., "Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> , 22:903-907 (1992).		
C14	Shimojo, N., et al., "Specificity of Peptide Binding by the HLA-A2.1 Molecule," <i>J. of Immunol.</i> 143(9):2939-2947 (November 1, 1989).		
C15	Carreno, B.M., et al., "HLA-B37 and HLA-A2.1 molecules bind largely nonoverlapping sets of peptides," <i>Proc. Natl. Acad. Sci. USA</i> , 87:3420-3424 (May 1990).		
C16	Henderson, R.A., et al., "HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation," <i>Science</i> 255:1264-1266 (10 February 1992).		
C17	Kannagi, M., et al., "Target Epitope in the Tax Protein of Human T-Cell Leukemia Virus Type I Recognized by Class I Major Histocompatibility Complex-Restricted Cytotoxic T Cells," <i>J. of Virol.</i> 66 (5) :2928-2933 (May 1992).		
C18	Falk, K., et al., "Allele-specific motifs revealed by sequencing of self-peptide eluted from MHC molecules," <i>Nature</i> 351:290-296 (23 May 1991).		
C19	Jardetzky, T.S., et al., "Identification of self peptides bound to purified HLA-B27," <i>Nature</i> 353:326-329 (September 26, 1991).		
C20	Hunt, D.F., et al., "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry," <i>Science</i> 255:1261-1263 (March 6, 1992).		
C21	Rotzschke, O., et al., "Naturally occurring peptide antigens derived from the MHC class-I-restricted processing pathway," <i>Immunology Today</i> 12(12):447-455 (1991).		
C22	De Bruijn, M.L.H., et al., "Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses," <i>Eur. J. Immunol.</i> 21:2963-2970 (1991).		
C23	Pamer, E.G., et al., "Precise prediction of a dominant class I MHC-restricted epitope of <i>Listeria monocytogenes</i> ," <i>Nature</i> 353:852-855 (October 31, 1991).		
C24	DiBrino, M. et al., "Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides," <i>Proc. Nat'l. Acad. Sci. USA</i> 90: 1508-1512 (February 1993).		
<u>W</u> C25	Paul, W.F. (ed.), <i>Fundamental Immunology</i> , 2nd ed., pp. 473-487 (1989), Raven Press, NY		

Am. in

12/30/93

FORM PTO-1449 (Modified)		Attorney Docket No. 018623-005091/EPI 0050.91US	Serial No.: 09/017,524
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Ralph T. Kubo et al.	
		Filing Date: 2/3/98	Group: not assigned
<u>ind</u> C26	Romero et al., <i>J. Immunol.</i> 174: 603-612 (Sept. 1991), "H-2Kd-restricted antigenic peptides share a simple binding motif".		
C27	Sette et al., <i>Proc. Nat'l. Acad. Sci. USA</i> 86: 3296-3300 (1989), "Prediction of major histocompatibility complex binding regions by sequence pattern analysis".		
C28	Krieger et al., <i>J. Immunol.</i> 146: 2331-2340 (1991) "Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition".		
C29	Sette et al., <i>J. Immunol.</i> 147: 3893-3900 (1991), "Random association between the peptide repertoire of A2.1 Class I and several different DR Class II molecules".		
C30	Knuth et al., <i>Curr. Opinion Immunol.</i> (1991) 3: 659-664, "Cellular and humoral immune responses against cancer: implications for cancer vaccines".		
C31	Viret et al., <i>Eur. J. Immunol.</i> (1993) 23: 141-146, "Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes".		
C32	Hayashi et al., <i>J. Immunol.</i> (1992) 149: 1223-1229, "Molecular cloning and characterization of the gene encoding mouse melanoma antigen by cDNA library transfection".		
C33	Storkus et al., <i>J. Immunol.</i> (Oct. 1, 1993) 151: 3719-3727, "Identification of human melanoma peptides recognized by Class I restricted tumor infiltrating T lymphocytes".		
C34	Slingluff et al., <i>J. Immunol.</i> (April 1, 1993) 150: 2955-2960, "Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes".		
C35	Van der Bruggen et al., <i>Science</i> (Dec. 13, 1991) 254: 1643-1647, "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma".		
C36	Maryanski et al., <i>Cell</i> 60: 63-72 (1990) "Competitor analogs for defined T cell antigens: peptides incorporating a putative binding motif and polyproline or polyglycine spacers".		
C37	Bjorkman et al., "Structure of the human class I histocompatibility antigen HLA-A2," <i>Nature</i> (1987) 329: 506		
C38	Buus et al., <i>Science</i> (1988) 242: 1045-1047 "Autologous peptides constitutively occupy the antigen binding site on Ia"		
C39	Celis et al., <i>Mol. Immunol.</i> (1994) 31: 1423-1430, "Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles"		
C40	Rammensee et al., <i>Immunogenet.</i> (1995) 41: 178-228, "MHC ligands and peptide motifs: first listing"		
C41	Rotzschke et al., <i>Nature</i> (Nov. 15, 1990) 348: 252-254, "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells"		
C42	Rotzschke et al., <i>Science</i> (July 20, 1990) 249: 283-287, "Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y"		
C43	Jiang et al., <i>Science</i> (May 22, 1992) 256: 1213-1215, "Role of CD8* T cells in murine experimental allergic encephalomyelitis"		
<u>ind</u> C44	Koh et al., <i>Science</i> (May 22, 1992) 256: 1210-1213, "Less mortality but more relapses in experimental allergic encephalomyelitis in CDB ^{-/-} mice"		

Handwritten signature

12/30/94

FORM PTO-1449 (Modified)		Attorney Docket No. 018623-005091/EPI 0050.91US	Serial No.: 09/017,524
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Ralph T. Kubo et al.	
		Filing Date: 2/3/98	Group: not assigned
<u>MD</u> C45	Miller et al., Proc. Nat'l Acad. Sci. USA (January 1992) 89: 421-425, "Suppressor T cells generated by oral tolerization to myelin basic protein to suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering"		
<u>MD</u> C46	Foon, Cancer Res. (April 1, 1989) 49: 1621-1639, "Biological response modifiers: the new immunotherapy"		
<u>MD</u> C47	Parker et al., J. Immunol. (December 1, 1992) 149:3580-3587, "Sequence motifs important for peptide binding to the human MHC Class I molecule, HLA-A2"		
— C48	BRUSS, V. A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation. J. Virology. December 1997, Vol. 71, No. 12, pages 9350-9357.		
— C49	PREISLER-ADAMS, S. et al. Complete nucleotide sequence of a hepatitis B virus, subtype adw2, and identification of three types of C open reading frame. Nucleic Acids Res. 1993, Vol. 21, No. 9, pages 2258.		
<u>MD</u> C50	RAMMENSEE, H. et al. Peptides naturally presented by MHC Class I molecules. Annu. Rev. Immunol. 1993, Vol. 11, pages 213-244.		
— C51	ENGELHARD, V. et al. Structure of peptides associated with MHC Class I molecules. Curr. Opin. Immunol. 1994, Vol. 6, pages 13-23.		
— C52	Aichele, P. et al., J. Exp. Med. 171:1815-1820 (May, 1990), "Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide".		
— C53	Kast, W.M. et al., Proc. Nat'l Acad. Sci. 88:2283-2287 (March, 1991), "Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide".		
— C54	Deres, K. et al., Nature 342:561-564 (30 November 1989), "In vivo priming of virus-specific cytotoxic lymphocytes with synthetic lipopeptide vaccine".		
— C55	Kumar, V. et al., PNAS 87:1337-1341 (February 1990), "Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties".		
— C56	Cordingley, et al., J.B.C. 265: 9062-65 (1990)		
— C57	Maryanski, J.L. et al., J. Exp. Med. 167:1391-1405 (April 1988), "Synthetic peptides as antigens and competitors in recognition by H2-restricted cytolytic T cell specific for HLA".		
— C58	Patarroyo, M.E. et al., Nature 328:629-632 (August 1987), "Induction of protective immunity against experimental infection with malaria using synthetic peptides".		
— C59	Robson, K. et al., Nature 335:79-82 (1988).		
EXAMINER <u>MD</u> DATE CONSIDERED <u>12/30/90</u>			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		Attorney Docket No.: 18623-005091US		Application No.: 09/017,524		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Ralph T. Kubo et al.				
		Filing Date: February 3, 1998		Group: 1644		
Reference Designation		U.S. PATENT DOCUMENTS			Page 1	
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
<u>MS</u> DA	EP 0 728 764 A (AJINOMOTO CO.)	28 August 1996	Europe			
<u>DB</u>	WO 95/11255 (AJINOMOTO CO.)	27 April 1995	PCT			
<u>MD</u> DC	WO 94/20127 (CYTEL CORPORATION)	15 September 1994 (1994-09-15)	PCT			
<u>MD</u> DD	WO 95/23234 (LUDWIG INSTITUTE)	31 August 1995 (1995-08-31)	PCT			
<u>MD</u> DE	WO 97/04802 (PACIFIC NORTHWEST CANCER FOUNDATION)	13 February 1997 (1997-02-13)	PCT			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
<u>DF</u>	CHEMICAL ABSTRACTS, vol. 125, no. 19, 4 November 1996 (1996-11-04) Columbus, Ohio, US; abstract no. 245055 P. SHANKAR ET AL.: "Three regions of HIV-1 gp160 contains clusters of immunodominant CTL epitopes" XP002122110 & IMMUNOLOGY LETTERS., vol. 52, no. 1, January 1996 (1996-01), pages 23-30, AMSTERDAM., NL ISSN: 0165-2478					
EXAMINER	DATE CONSIDERED		12/30/00			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.